Browse > Article
http://dx.doi.org/10.4062/biomolther.2013.010

Zanamivir Oral Delivery: Enhanced Plasma and Lung Bioavailability in Rats  

Shanmugam, Srinivasan (Pharm. R&D Institute, Hanmi Pharm. Co., Ltd.)
Im, Ho Taek (Pharm. R&D Institute, Hanmi Pharm. Co., Ltd.)
Sohn, Young Taek (College of Pharmacy, Duksung Women's University)
Kim, Kyung Soo (Pharm. R&D Institute, Hanmi Pharm. Co., Ltd.)
Kim, Yong-Il (Pharm. R&D Institute, Hanmi Pharm. Co., Ltd.)
Yong, Chul Soon (College of Pharmacy, Yeungnam University)
Kim, Jong Oh (College of Pharmacy, Yeungnam University)
Choi, Han-Gon (College of Pharmacy, Hanyang University)
Woo, Jong Soo (Pharm. R&D Institute, Hanmi Pharm. Co., Ltd.)
Publication Information
Biomolecules & Therapeutics / v.21, no.2, 2013 , pp. 161-169 More about this Journal
Abstract
The objective of this study was to enhance the oral bioavailability (BA) of zanamivir (ZMR) by increasing its intestinal permeability using permeation enhancers (PE). Four different classes of PEs (Labrasol$^{(R)}$, sodium cholate, sodium caprate, hydroxypropyl ${\beta}$-cyclodextrin) were investigated for their ability to enhance the permeation of ZMR across Caco-2 cell monolayers. The flux and $P_{app}$ of ZMR in the presence of sodium caprate (SC) was significantly higher than other PEs in comparison to control, and was selected for further investigation. All concentrations of SC (10-200 mM) demonstrated enhanced flux of ZMR in comparison to control. The highest flux (13 folds higher than control) was achieved for the formulation with highest SC concentration (200 mM). The relative BA of ZMR formulation containing SC (PO-SC) in plasma at a dose of 10 mg/kg following oral administration in rats was 317.65% in comparison to control formulation (PO-C). Besides, the $AUC_{0-24\;h}$ of ZMR in the lungs following oral administration of PO-SC was $125.22{\pm}27.25$ ng hr $ml^{-1}$ with a $C_{max}$ of $156.00{\pm}24.00$ ng/ml reached at $0.50{\pm}0.00$ h. But, there was no ZMR detected in the lungs following administration of control formulation (PO-C). The findings of this study indicated that the oral formulation PO-SC containing ZMR and SC was able to enhance the BA of ZMR in plasma to an appropriate amount that would make ZMR available in lungs at a concentration higher (>10 ng/ml) than the $IC_{50}$ concentration of influenza virus (0.64-7.9 ng/ml) to exert its therapeutic effect.
Keywords
Zanamivir oral delivery; Permeation enhancer; Bioavailability enhancement; Sodium caprate; Influenza;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Lindmark, T., Schipper, N., Lazorova, L., de Boer, A. G. and Artursson, P. (1998) Absorption enhancement in intestinal epithelial Caco-2 monolayers by sodium caprate: assessment of molecular weight dependence and demonstration of transport routes. J. Drug Target. 5, 215-223.   DOI   ScienceOn
2 Artursson, P., Palm, K. and Luthman, K. (2001) Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 46, 27-43.   DOI   ScienceOn
3 Aungst, B. J. (2000) Intestinal permeation enhancers. J. Pharm. Sci. 89, 429-442.   DOI   ScienceOn
4 Baughman, R. A., Kapoor, S. C., Agarwal, R. K., Kisicki, J., Catella-Lawson, F. and FitzGerald, G. A. (1998) Oral delivery of anticoagulant doses of heparin. A randomized, double-blind, controlled study in humans. Circulation 98, 1610-1615.   DOI   ScienceOn
5 Boonyapiwat, B., Sarisuta, N. and Kunastitchai, S. (2011) Characterization and in vitro evaluation of intestinal absorption of liposomes encapsulating zanamivir. Curr. Drug Deliv. 8, 392-397.   DOI   ScienceOn
6 Buclin, T., Cosma Rochat, M., Burckhardt, P., Azria, M. and Attinger, M. (2002) Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J. Bone Miner. Res. 17, 1478-1485.   DOI   ScienceOn
7 Caballero, E., Prieto, C., Ruiz, M. and Azanza, J. R. (2000) Zanamivir: new therapeutic option for influenza. Rev. Med. Univ. Navarra 44, 56-61.
8 Calfee, D. P., Peng, A. W., Cass, L. M., Lobo, M. and Hayden, F. G. (1999) Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob. Agents Chemother. 43, 1616-1620.
9 Cano-Cebrian, M. J., Zornoza, T., Granero, L. and Polache, A. (2005) Intestinal absorption enhancement via the paracellular route by fatty acids, chitosans and others: a target for drug delivery. Curr. Drug Deliv. 2, 9-22.   DOI   ScienceOn
10 Colman, P. M. (2005). Zanamivir: an influenza virus neuraminidase inhibitor. Expert Rev. Anti. Infect. Ther. 3, 191-199.   DOI   ScienceOn
11 de Jong, M. D., Tran, T. T., Truong, H. K., Vo, M. H., Smith, G. J., Nguyen, V. C., Bach, V. C., Phan, T. Q., Do, Q. H., Guan, Y., Peiris, J. S., Tran, T. H. and Farrar, J. (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353, 2667-2672.   DOI   ScienceOn
12 Dunn, C. J. and Goa, K. L. (1999) Zanamivir: a review of its use in influenza. Drugs 58, 761-784.   DOI   ScienceOn
13 Elliott, M. (2001) Zanamivir: from drug design to the clinic. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 356, 1885-1893.   DOI   ScienceOn
14 van Hoogdalem, E. J., de Boer, A. G. and Breimer, D. D. (1991b) Pharmacokinetics of rectal drug administration, Part II. Clinical applications of peripherally acting drugs, and conclusions. Clin. Pharmacokinet. 21, 110-128.   DOI   ScienceOn
15 Stephenson, I., Democratis, J., Lackenby, A., McNally, T., Smith, J., Pareek, M., Ellis, J., Bermingham, A., Nicholson, K. and Zambon, M. (2009) Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin. Infect. Dis. 48, 389-396.   DOI   ScienceOn
16 Takahashi, K., Murakami, T., Yumoto, R., Hattori, T., Higashi, Y. and Yata, N. (1994) Decanoic acid induced enhancement of rectal absorption of hydrophilic compounds in rats. Pharm. Res. 11, 1401-1404.   DOI
17 van Hoogdalem, E., de Boer, A. G. and Breimer, D. D. (1991a) Pharmacokinetics of rectal drug administration, Part I. General considerations and clinical applications of centrally acting drugs. Clin. Pharmacokinet. 21, 11-26.   DOI   ScienceOn
18 von Itzstein, M. (2007) The war against influenza: discovery and development of sialidase inhibitors. Nat. Rev. Drug Discov. 6, 967-974.   DOI   ScienceOn
19 Whitehead, K., Karr, N. and Mitragotri, S. (2008a) Discovery of synergistic permeation enhancers for oral drug delivery. J. Control. Release 128, 128-133.   DOI   ScienceOn
20 Whitehead, K., Karr, N. and Mitragotri, S. (2008b) Safe and effective permeation enhancers for oral drug delivery. Pharm. Res. 25, 1782-1788.   DOI
21 Whitehead, K. and Mitragotri, S. (2008) Mechanistic analysis of chemical permeation enhancers for oral drug delivery. Pharm. Res. 25, 1412-1419.   DOI
22 Yee, S. (1997) In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man--fact or myth. Pharm. Res. 14, 763-766.   DOI   ScienceOn
23 Nissan, A., Ziv, E., Kidron, M., Bar-On, H., Friedman, G., Hyam, E. and Eldor, A. (2000) Intestinal absorption of low molecular weight heparin in animals and human subjects. Haemostasis 30, 225-232.
24 Maher, S., Leonard, T. W., Jacobsen, J. and Brayden, D. J. (2009) Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic. Adv. Drug Deliv. Rev. 61, 1427-1449.   DOI   ScienceOn
25 Miller, J. M., Dahan, A., Gupta, D., Varghese, S. and Amidon, G. L. (2010) Enabling the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir. Mol. Pharm. 7, 1223-1234.   DOI   ScienceOn
26 Mori, K. (1953) Production of gastric lesions in the rat by the diet containing fatty acids. Gan 44, 421-427.
27 Press, B. and Di Grandi, D. (2008) Permeability for intestinal absorption: Caco-2 assay and related issues. Curr. Drug Metab. 9, 893-900.   DOI   ScienceOn
28 Raoof, A. A., Ramtoola, Z., McKenna, B., Yu, R. Z., Hardee, G. and Geary, R. S. (2002) Effect of sodium caprate on the intestinal absorption of two modified antisense oligonucleotides in pigs. Eur. J. Pharm. Sci. 17, 131-138.   DOI   ScienceOn
29 Reece, P. A. (2010) Zanamivir for the treatment of avian influenza infections in humans. Expert Rev. Clin. Pharmacol. 3, 25-29.   DOI   ScienceOn
30 Rege, B. D., Yu, L. X., Hussain, A. S. and Polli, J. E. (2001) Effect of common excipients on Caco-2 transport of low-permeability drugs. J. Pharm. Sci. 90, 1776-1786.   DOI   ScienceOn
31 Salama, N. N., Eddington, N. D. and Fasano, A. (2006) Tight junction modulation and its relationship to drug delivery. Adv. Drug Deliv. Rev. 58, 15-28.   DOI   ScienceOn
32 Shelton, M. J., Lovern, M., Ng-Cashin, J., Jones, L., Gould, E., Gauvin, J. and Rodvold, K. A. (2011) Zanamivir pharmacokinetics and pulmonary penetration into epithelial lining fluid following intravenous or oral inhaled administration to healthy adult subjects. Antimicrob. Agents Chemother. 55, 5178-5184.   DOI   ScienceOn
33 Sawada, T., Ogawa, T., Tomita, M., Hayashi, M. and Awazu, S. (1991) Role of paracellular pathway in nonelectrolyte permeation across rat colon epithelium enhanced by sodium caprate and sodium caprylate. Pharm. Res. 8, 1365-1371.   DOI
34 Sharma, P., Varma, M. V., Chawla, H. P. and Panchagnula, R. (2005a) Absorption enhancement, mechanistic and toxicity studies of medium chain fatty acids, cyclodextrins and bile salts as peroral absorption enhancers. Farmaco 60, 884-893.   DOI   ScienceOn
35 Sharma, P., Varma, M. V., Chawla, H. P. and Panchagnula, R. (2005b) Relationship between lipophilicity of BCS class III and IV drugs and the functional activity of peroral absorption enhancers. Farmaco 60, 870-873.   DOI   ScienceOn
36 Smetanova, L., Stetinova, V., Svoboda, Z. and Kvetina, J. (2011) Caco-2 cells, biopharmaceutics classification system (BCS) and biowaiver. Acta Medica (Hradec Kralove, Czech Repub) 54, 3-8.   DOI
37 Fick, J., Lindberg, R. H., Tysklind, M., Haemig, P. D., Waldenstrom, J., Wallensten, A. and Olsen, B. (2007) Antiviral oseltamivir is not removed or degraded in normal sewage water treatment: implications for development of resistance by influenza A virus. PLoS One 2, e986.   DOI
38 Freund, B., Gravenstein, S., Elliott, M. and Miller, I. (1999) Zanamivir: a review of clinical safety. Drug Saf. 21, 267-281.   DOI   ScienceOn
39 Goldberg, M. and Gomez-Orellana, I. (2003) Challenges for the oral delivery of macromolecules. Nat. Rev. Drug Discovery 2, 289-295.   DOI   ScienceOn
40 Gomez-Orellana, I. (2005) Strategies to improve oral drug bioavailability. Expert Opin. Drug Deliv. 2, 419-433.   DOI   ScienceOn
41 Le, Q. M., Kiso, M., Someya, K., Sakai, Y. T., Nguyen, T. H., Nguyen, K. H., Pham, N. D., Ngyen, H. H., Yamada, S., Muramoto, Y., Horimoto, T., Takada, A., Goto, H., Suzuki, T., Suzuki, Y. and Kawaoka, Y. (2005) Avian flu: isolation of drug-resistant H5N1 virus. Nature 437, 1108.   DOI   ScienceOn
42 Gupta, S. V., Gupta, D., Sun, J., Dahan, A., Tsume, Y., Hilfinger, J., Lee, K. D. and Amidon, G. L. (2011) Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach. Mol. Pharm. 8, 2358-2367.   DOI
43 Jorgensen, J., Holtug, K., Jeppesen, P. B. and Mortensen, P. B. (1998) Human rectal absorption of short- and medium-chain C2-C10 fatty acids. Scand. J. Gastroenterol. 33, 590-594.   DOI
44 Kidron, M., Dinh, S., Menachem, Y., Abbas, R., Variano, B., Goldberg, M., Arbit, E. and Bar-On, H. (2004) A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects. Diabetic Med. 21, 354-357.   DOI   ScienceOn
45 Lee, W. A., Ennis, R. D., Longenecker, J. P. and Bengtsson, P. (1994) The bioavailability of intranasal salmon calcitonin in healthy volunteers with and without a permeation enhancer. Pharm. Res. 11, 747-750.   DOI
46 Leone-Bay, A., Sato, M., Paton, D., Hunt, A. H., Sarubbi, D., Carozza, M., Chou, J., McDonough, J. and Baughman, R. A. (2001) Oral delivery of biologically active parathyroid hormone. Pharm. Res. 18, 964-970.   DOI   ScienceOn
47 Li, W., Escarpe, P. A., Eisenberg, E. J., Cundy, K. C., Sweet, C., Jakeman, K. J., Merson, J., Lew, W., Williams, M., Zhang, L., Kim, C. U., Bischofberger, N., Chen, M. S. and Mendel, D. B. (1998) Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob. Agents Chemother. 42, 647-653.   DOI
48 Lindmark, T., Nikkila, T. and Artursson, P. (1995) Mechanisms of absorption enhancement by medium chain fatty acids in intestinal epithelial Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. 275, 958-964.